Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
نویسندگان
چکیده
This Issue Brief reports on changes in manufacturers' prescription drug prices during the first three months of 2004 (January through March) for the brand name prescription drugs most widely used by Americans age 50 and over. This report is the first quarterly update in an ongoing study of changes in drug manufacturer prices-that is, manufacturers' prices charged for drugs they sold to wholesalers. A baseline study published in May 2004 by the AARP Public Policy Institute identified steady increases in the average annual manufacturer price from calendar year 2000 through calendar year 2003. This report's focus is on changes in the prices that brand name drug manufacturers charge to wholesalers for sales to retail pharmacies. The manufacturer's charge to wholesalers is the most substantial component of a prescription drug's retail price. When there is an increase in the manufacturer price to wholesalers for a brand name drug, this added cost is generally passed on as a similar percent change in the retail price to most prescription purchasers. The report presents three measures of price change (see methodological appendix). The first set of findings are annual rates of change in manufacturers' prices for widely used brand name drugs, using both rolling average and point-to-point estimates; information is presented on percentage change in manufacturer price and on potential dollar changes in consumer spending. The second set of findings are three-month percentage changes in prices (i.e., changes from December 31, 2003 through March 31, 2004); the distribution of percentage price changes is shown, as well as differences in average percentage price changes by manufacturer and by therapeutic category.
منابع مشابه
Summaries for patients. Price comparison for brand name drugs purchased through the Internet from Canada- and U.S.-based pharmacies.
M.J. Eisenberg. What is the problem and what is known about it so far? The costs of prescription drugs present a problem for many Americans. The prices of prescription drugs tend to be higher in the United States than in some other countries. Consequently, many Americans purchase prescription drugs from Canadian pharmacies through the Internet. However, no study has systematically quantified th...
متن کاملPrescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
Over the past two decades, courts have consistently ruled that the manufacturer of a brand-name prescription drug cannot be liable for injuries suffered by those taking generic imitations of its product. This meant that a patient injured by a generic drug could have no remedy at all because in many instances the generic drug manufacturer would escape liability on the ground that it did not prod...
متن کاملFactors influencing hematologists-oncologists’ prescription of chemotherapy drugs in cancer treatment in Iran: aninterview-questionnaire study
Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, and targeted therapy. The choice of treatment dependson the type and stage of the cancer. Chemotherapy drugs play an important role in cancer treatment. The objective of this interview-questionnaire study is to explore what influences Iranian hematologists-oncologists’ prescription when prescribing chemotherapy...
متن کاملAMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
The methods by which the U.S. health care system pays for prescription drugs have faced increasing scrutiny in recent years. Two key developments have emerged: (a) congressional enactment of important changes in the basis for payments for prescription drugs in the Medicare and Medicaid programs; and (b) a March 2009 decision in a federal class action lawsuit that alleged fraudulent manipulation...
متن کاملRising Health Care Costs and Life-Cycle Management in the Pharmaceutical Market
The problem of rising prescription drug costs has emerged as a critical policy issue around the world, particularly in the United States. These costs strain the budgets of patients and health insurers, and directly contribute to adverse health outcomes by reducing adherence to important medications. Drug spending is driven by brand-name drugs, which currently account for about 20% of all prescr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Issue Brief (Public Policy Institute (American Association of Retired Persons))
دوره IB69 شماره
صفحات -
تاریخ انتشار 2004